Background: Lung transplant recipients are at very high risk of skin cancer. Omega-3 fatty acids
Introduction 1
Despite their potential to prevent skin cancer (15) , no studies have evaluated omega-3 FA 28 supplementation in LTRs to reduce skin cancer risk. We therefore conducted a randomized controlled 29 pilot trial to assess the feasibility and acceptability, and safety of daily supplementation with omega- 3 30 FAs to prevent skin cancers in these patients. To inform future trials, we also assessed if omega-3 FA 31 supplementation reduced skin cancer incidence. 32 33
Methods 34

Study participants 35
LTRs aged 18 years or more who were at least one year post-transplant and able to attend baseline 36 and follow-up clinical assessments were recruited in the outpatient clinic at The Prince Charles 37
Hospital, Brisbane, Australia between November, 2014 and February, 2015. LTRs unable to give 38 informed consent, who had fish or soy allergy, were unable to take gelatin, had a bleeding disorder, 39 bleeding episode in the last 3 months or were taking anti-thrombotic medication or omega-3 FA 40 supplements, and those who were pregnant or at negligible risk of skin cancer due to innately dark or 41 black skin, were not eligible. The trial was approved by two institutional ethics committees and 42 registered with the ANZ Clinical Trial Registry (12614000873628). The full trial protocol can be 43 obtained from the authors on request. Study protocols were in agreement with the guidelines set forth 44 by Declaration of Helsinki, and all study participants provided written informed consent. 45
46
Randomization and intervention 47
Trial participants were required to take 4 x 1g capsules daily containing 3.36g total omega-3 FAs 55 (46% eicosapentaenoic acid (EPA) ethyl ester, 38% docosahexaenoic acid (DHA) ethyl ester) 56 (Omacor®) or 4 x 1g placebo capsules daily containing 4g of olive oil, as supplied by Pronova 57 BioPharma, Lysaker, Norway. 58
59
Data collection 60
Participants completed questionnaires to provide socio-demographic information, and report their 61 tanning ability and usual sun protection behaviors prior to randomization and at end of the study. A 62 food frequency questionnaire was administered to measure usual dietary intake. Dates of 63 transplantation and immunosuppression regimens were obtained from medical records. Skin color was 64 assessed and categorized by dermatologists at baseline. All participants underwent full skin 65 examination by dermatologically-trained physicians at recruitment and conclusion of the trial. 66
Suspicious lesions were mapped on a body chart and affected participants were referred for further 67 management. Histological confirmation of lesions diagnosed at study clinics or in the interim (as 68 reported by participants during 3-monthly visits) was obtained through patients' referral physicians 69 and/or pathology laboratories. All adverse events during the study period were recorded regardless of 70 relation to the intervention. 71
72
Fasting blood samples were collected prior to randomization and at end of the intervention. Samples 73 were centrifuged within 45 minutes of collection, and separated plasma was stored at -11 to -25°C 74 until analysis. Plasma saturated and unsaturated fatty acids were assayed using procedures described 75 previously (17) . Briefly, acidic hydrolysis of plasma specimens was followed by basic hydrolysis and 76 re-acidification. Hexane extraction then proceeded to derivatization with pentafluorobenzyl (PFB) 77 bromide. Separation and detection of the corresponding PFB-esters were accomplished by capillary 78 gas chromatography-electron capture negative ion mass spectrometry. Quantification was enabled by 79 plotting the response ratios of samples and quality control against the standard calibration curve. 80
As this was a pilot study, no formal sample size calculation was carried out. However, we aimed to 83 enroll sufficient numbers to show if the interventions were acceptable, the clinical evaluations were 84 feasible and to provide a basis for calculating the sample size of a future definitive trial. 85
86
Feasibility and acceptability of the intervention were measured by rates of participation and retention 87
and by adherence to daily supplementation as indicated by changes in the specific plasma fatty acids 88 assessed, namely EPA, DHA, total omega-3 FA and omega-3: omega-6 FA ratio. Analysis of 89 covariance (ANCOVA) was used to compare plasma FA status between treatment groups at the end 90 of the study, accounting for potential heterogeneity of baseline plasma omega-3 FA status (18) . Since 91 plasma omega-3 FAs typically are not normally distributed, all values were log-transformed before 92 undertaking ANCOVA. Safety was indicated by the number of participants who experienced adverse 93 events determined to be possibly, probably, or definitely related to the allocated intervention. 94
95
The potential effect of omega-3 FA supplementation on skin cancer incidence was assessed by the 96 difference in incidence of skin cancer in the intervention period between the active and placebo 97 treatment groups. Skin cancer outcomes were SCC, BCC, total SCC and BCC combined, and total 98 skin malignancies (SCC, BCC, melanoma, other rare skin malignancies). Person-based incidence was 99 calculated as the rate of persons newly affected by skin cancer in each intervention group. ORs with 100 95% confidence intervals (CIs) were calculated by logistic regression to estimate the risk of 101 developing any new skin cancer by allocation status. Tumor-based incidence, the rate of total new 102 skin cancers was also estimated. Relative risks (RRs) with 95% CIs were calculated using generalized 103 linear models with negative binomial distribution and person-time of follow-up as offset. All models 104
were adjusted for the stratification variable, previous skin cancer and all analyses were performed 105 using SAS version 9.4 (SAS Institute, Inc., Cary, NC, US).
7
Of 127 LTRs attending the outpatient clinic, 21 were ineligible or unable to take part, and of the 110 remaining 106, 57 (54 %) declined, leaving 49 LTRs who agreed and consented to participate ( Figure  111 1). Of these, 25 LTRs (median age 55 years) were allocated to FA acid supplements, and 24 (median 112 age 54 years), were allocated to placebo supplements. Other baseline characteristics relevant to skin 113 cancer risk, namely sex, education, skin color, occupational sun exposure, and years since 114 transplantation were broadly similar between the groups, though more participants with skin prone to 115 sunburn were allocated to placebo (17; 71%) than to omega-3 supplements (10; 40%), and fewer in 116 the placebo (2; 8%) than omega-3 FA (8; 36%) group never applied sunscreen to the head/neck in 117 summer (Table 1) provided fasting blood samples at study's end (the remainder provided non-fasting samples that were 130 not informative). At baseline, plasma levels of EPA, DHA, total omega-3 FAs and omega-3: omega-6 131 ratio were comparable between the two groups; after 12-months' intervention, geometric mean values 132 of all these measures increased substantially, and significantly more in the omega-3 FA than placeboThere were no serious adverse events related to omega-3 FA supplementation though two patients 137 randomized to omega-3 FA supplements complained of mild gastrointestinal discomfort and two had 138 minor bleeding episodes. In the placebo arm, five had gastrointestinal discomfort, three minor 139 bleeding events and one reported renal problems. 140
141
Skin cancer 142
In addition to baseline and end-of-study skin examinations, 3 patients in the omega-3 FA group and 9 143 in the placebo group had external dermatologic evaluations, resulting in a median (range) of biopsies 144 per patient of 0 (0-4) and 0 (0-21) in the groups, respectively. Incidence of persons developing new 145 skin cancer in the total intervention period was reduced by two-thirds in the omega-3 FA group 146 though not significantly (Table 3) To the best of our knowledge, this is the first randomized, placebo-controlled trial of omega-3 FA 160 supplementation to reduce skin cancer occurrence in LTRs. We have shown that omega-3 FA 161 supplementation among these patients is feasible and safe and moreover that omega-3 FA9 increase in plasma omega-3 FAs, and there were no serious adverse outcomes. The incidence of skin 165 cancers decreased by a half to two-thirds in the omega-3 FA group compared with controls. 166
167
Regarding adherence in particular, plasma EPA and omega-3:omega-6 fatty acid ratio showed a 168 substantial increase in the group allocated to omega-3 FA supplements, with a negligible increase in 169 EPA in the placebo group and a small decrease in the omega-3:omega-6 ratio. Only a few participants 170 did not adhere to the intervention, and only one reported they found 4 capsules daily excessive in 171 addition to their usual medications. Although adherence to medication among organ transplant 172 recipients is not well described (19, 20) , similar increases in biomarkers of omega-3 FA intake have 173 been reported, for example, in a randomized controlled trial (RCT) among kidney transplant recipients 174 allocated to either 6g of total omega-3 FAs or 6g of coconut oil daily for 12-months (21). Adherence 175 was assessed using plasma cholesterol esters and the results showed EPA concentration increased 176 from a median of 0.39 mol% (range 0.18 to 10.31) to 4.7 mol% (0.89 to 10.31) in the omega-3 FA 177 group but no change in controls after 6 months. Similar changes were seen among heart transplant 178 recipients who took omega-3 FA supplementation vs. placebo over a 12-month period (22) . In the 179 current study, omega-3 FA status also increased in some of the placebo group, in particular, one 180 participant's DHA level increased noticeably, but no other markers of omega-3 FA levels rose in the 181 placebo group. 182
183
Of 106 eligible patients, around half declined to participate in the trial. The most frequently reported 184 reasons were time constraints and lack of interest. However, once taking part, retention of participants 185 was high with 86% retention over the 12-month intervention period. Previous systematic reviews of 186
RCTs among kidney transplant recipients with omega-3 FA supplementation for longer than 3 months 187 reported attrition rates up to 32%, with lower attrition rates over shorter intervention periods (19) . 188
Although attrition was low in our study, we failed to obtain plasma FA status from some trial 189 participants mostly due to their non-fasting state when providing blood. Thus, to ensure that blood 190 collected from participants is usable in any future similar study, sending reminders ahead of collectionof blood via finger-pricks would reduce participants' burden. Concerning adverse events, participants 193 in the placebo group reported more than in the omega-3 FA group. All reported similar complaints 194 (mild gastrointestinal discomfort, episodes of unusual bleeding), consistent with reports in previous 195 studies that used omega-3 fatty acid supplements and olive oil as placebo (19, (23) (24) (25) . 196
197
When we explored the potential effectiveness of omega-3 FA supplementation for skin cancer 198 prevention, we found skin cancer development was reduced by half to two-thirds in the omega-3 FA 199 compared with the placebo group though in this pilot trial the decrease was not significant. prostaglandins, leukotrienes and hydroxy fatty acids with a generally anti-inflammatory and anti-211 carcinogenic profile (26) . Levels of omega-3 fatty acids vary in the diet, but are generally very low, 212 and correlate with the amounts found in serum and skin (27) . Their epidermal lipid content increases 213 on daily omega-3 fatty acid supplementation (14) . However, it appears that the omega-3: omega-6 214 fatty acid ratio is of greater relevance than the level of omega-3 fatty acids in protection of the skin 215 from ultraviolet radiation, as explained by their partial agonist effects (26) . Historically, amounts of 216 omega-3 and omega-6 fatty acids in the human diet were more balanced (28) . This is now skewed 217 towards omega-6 fatty acids in most populations; supplementation helps address this imbalance. 218 Therefore, achieving a higher ratio meant reduced pro-inflammatory eicosanoid metabolites and221 Limitations of this study include the allocation of more sunburn-prone participants to the placebo than 222 active treatment group. This imbalance may have influenced observed reduced skin cancer occurrence 223 in the omega-3 FA group. Further, the sample size was small and this study was not designed to 224 formally assess the clinical effectiveness of omega-3 FA supplementation. Thus, interpretation of 225 results requires caution. Another limitation of this pilot study, arising from its small number of 226 participants, was the additional imbalance in duration of immunosuppression between the randomized 227 groups whereby the placebo group had been immunosuppressed for a year longer on average. This 228 discrepancy could also have influenced the observed reduction of new skin cancer cases in the omega-229 3 fatty acid group compared with the placebo group. As well, the lack of capsule counts in the trial 230 participants was a potential limitation. After baseline, participants were to return their capsules at each 231 3-monthly visit but a number did not, making it impossible to assess adherence by capsule count. On 232 the other hand, capsule counts are known to be unreliable and may overestimate adherence (30, 31) , 233 while we showed high adherence in the active group by the measurement of plasma omega-3 FA 234 levels. Finally, the findings from this study in Australia may not be generalizable to LTRs elsewhere. 235
236
In conclusion, this randomized controlled pilot trial of omega-3 FA supplements to prevent skin 237 cancer among LTRs showed it to be feasible and safe, with most participants adhering to the 238 intervention and able to complete the study. We also explored the potential effects of omega-3 FA 239 supplementation on skin cancer incidence and found a potential protective effect in these high-risk 240 immunosuppressed patients. A full-scale RCT is now warranted. 241 Due to the missing information, not all total add to N=49 
